Open AccessPotentsial'nye vozmozhnosti metformina v profilaktike i lechenii onkologicheskikh zabolevaniy u bol'nykh sakharnym diabetom 2 tipa
Author(s) -
И И Дедов,
С А Бутрова,
M A Berkovskaya
Publication year - 2011
Publication title -
ožirenie i metabolizm
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/2071-8713-5190
Subject(s) - metformin , hyperinsulinemia , medicine , breast cancer , ampk , cancer , insulin resistance , oncology , endocrinology , ovarian cancer , insulin , cancer research , kinase , protein kinase a , biology , microbiology and biotechnology
Diabetes mellitus is associated with increased risk of several types of cancer, and also with increased cancer mortality. Chronichyperinsulinemia plays the main pathogenetic role in this association, which is mediated by a number of molecular mechanisms, describedin this issue. Drugs that increase insulin sensitivity and reduce hyperinsulinemia (metformin in the first place) display anticancereffect. Aside from the anticancer effect, mediated by reduction of insulin resistance, metformin may directly suppress cancer cellsgrowth and proliferation via stimulation of AMP kinase (AMPK). Antiproliferative action of metformin in breast and ovarian cancer isconfirmed in a number of experimental and clinical trials. Its found out that therapeutic effect of metformin in treatment of breast cancerdepends on the presence/absence of some molecular features of the tumor (for example, increased expression of HER2 and/or activationof p70S6K1). In order to specify mechanisms of action and effects of metformin in oncological practice several trials are being conductedor planned, most of all, in all subtypes of breast cancer. Confirmation of the anticancer effectiveness of metformin will promote an expansionof its use in clinical practice and in clinical oncology, particularly.